HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by von Tresckow, B. Articles by Hansen, H. P. Search for Related Content PubMed PubMed Citation Articles by von Tresckow, B. Articles by Hansen, H. P.

Simvastatin-dependent apoptosis in Hodgkin’s lymphoma cells and growth impairment of human Hodgkin’s tumors in vivo

From the Laboratory of Immunotherapy, Clinic I of Internal Medicine, University Hospital Cologne, Cologne, Germany, Center for Molecular Medicine, University Hospital Cologne, Cologne, Germany

Correspondence: Bastian von Tresckow, M.D., University Hospital Cologne, Laboratory of Immunotherapy, Department of Internal Medicine I, LFI-Eb.4, room 703, Kerpener Str. 62, 50924 Cologne, Germany. E-mail: bastian.von-tresckow{at}ukkoeln.de

Statins are used to treat hypercholesterolemia and seem to have a preventive effect against cancer through pleiotropic effects including prenylation-inhibition. So far nothing is known about the activity of statins or more specific prenylation-inhibitors in Hodgkin’s lymphoma (HL). We, therefore, evaluated the anti-HL activity of simvastatin and specific prenylation-inhibitors. Two µM Simvastatin induced caspase-related apoptosis via depletion of prenylation-substrates in several HL-cell lines. Furthermore, it effectively impaired tumor growth in a mouse model for HL. Since the prenylation-inhibitors FTI-277 and GGTI-298 were also effective against HL-cells, we conclude that statins and specific prenylation-inhibitors should be evaluated in HL patients.

Key words: lymphoma, apoptosis, growth control, statins.